CW Advisors LLC Acquires New Shares in GSK PLC Sponsored ADR $GSK

Key Points

• CW Advisors LLC has acquired a new stake in GSK PLC, purchasing 16,770 shares valued at approximately $648,000 during the first quarter.
• GSK recently reported earnings of $1.23 per share, exceeding analysts' expectations, with quarterly revenue of $10.64 billion, significantly higher than the forecasted $7.92 billion.
• The company has announced a quarterly dividend of $0.4206 per share, leading to an annualized dividend yield of 4.2%, despite a current dividend payout ratio of 77.78%.

CW Advisors LLC bought a new position in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 16,770 shares of the pharmaceutical company's stock, valued at approximately $648,000.

Other large investors also recently made changes to their positions in the company. Brighton Jones LLC bought a new position in shares of GSK during the fourth quarter worth approximately $528,000. First Hawaiian Bank increased its stake in shares of GSK by 18.8% during the first quarter. First Hawaiian Bank now owns 101,039 shares of the pharmaceutical company's stock worth $3,914,000 after purchasing an additional 15,987 shares during the period. Barclays PLC increased its stake in shares of GSK by 84.2% during the fourth quarter. Barclays PLC now owns 49,628 shares of the pharmaceutical company's stock worth $1,678,000 after purchasing an additional 22,689 shares during the period. Crestline Management LP bought a new position in shares of GSK during the fourth quarter worth approximately $1,047,000. Finally, Rehmann Capital Advisory Group increased its stake in shares of GSK by 9.3% during the fourth quarter. Rehmann Capital Advisory Group now owns 6,128 shares of the pharmaceutical company's stock worth $207,000 after purchasing an additional 520 shares during the period. Institutional investors own 15.74% of the company's stock.

GSK Price Performance

GSK stock traded up $0.24 during mid-day trading on Friday, reaching $39.68. 3,590,956 shares of the company were exchanged, compared to its average volume of 3,181,567. The company has a fifty day simple moving average of $38.40 and a 200-day simple moving average of $38.24. GSK PLC Sponsored ADR has a 12 month low of $31.72 and a 12 month high of $44.26. The company has a debt-to-equity ratio of 1.07, a current ratio of 0.87 and a quick ratio of 0.57. The firm has a market cap of $80.82 billion, a PE ratio of 18.37, a PEG ratio of 1.72 and a beta of 0.51.

GSK (NYSE:GSK - Get Free Report) last issued its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. The firm had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The company's revenue was up 1.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.43 EPS. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, equities research analysts expect that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current fiscal year.

GSK Cuts Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be issued a $0.4206 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend is Friday, August 15th. GSK's dividend payout ratio (DPR) is currently 77.78%.

Analyst Ratings Changes

A number of research firms have commented on GSK. Wall Street Zen upgraded GSK from a "hold" rating to a "buy" rating in a research note on Sunday, August 3rd. Berenberg Bank restated a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Six investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Reduce" and an average target price of $37.38.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.